Artios Pharma Limited
A DNA Damage Response (DDR)-focused biotechnology company pioneering DDR-based therapeutics for cancer.
Last updated September 1, 2026
Overview
Artios Pharma is a biotechnology company focused on DNA Damage Response (DDR)-based therapeutics for cancer. It was founded by industry-leading experts who pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs. The company is advancing a pipeline of product candidates with first- and best-in-class potential, including alnodesertib (ATR inhibitor) and ART6043 (Polθ inhibitor).
History
Artios Pharma is a company in Cambridge, United Kingdom. It was founded by industry-leading experts having pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs. The company is focused on DNA Damage Response (DDR)-based therapeutics for cancer.
Products and positioning
alnodesertib
ATR inhibitor
ART6043
Polθ inhibitor
Flagship businesses
- alnodesertib - ATR inhibitor
- ART6043 - Polθ inhibitor
Leadership
| Name | Title | Tenure |
|---|---|---|
| Michael T. Andriole | President, Chief Executive Officer, and Director | — |
Sources
Cite this profile: Cite the canonical profile. /brand-wiki/artios-pharma-limited-united-kingdom · Editorial policy · How profiles are compiled